Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02635672 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Vincerx Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
NCT02635672: Completed Phase 1 study, sponsored by Vincerx Pharma.
NCT02635672 is a Phase 1 study that has completed, run by Vincerx Pharma. The registered enrollment target is 110 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02635672, a Phase 1 study, has completed, sponsored by Vincerx Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
Study Summary
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).
Interventions
- DRUG Keytruda
- DRUG VIP152 (BAY 1251152)
- DRUG VIP152 (BAY 1251152) 30 mg
- DRUG VIP152 (BAY 1251152) 15 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2016-02-10 |
| Est. Completion | 2024-11-11 |
| Phase | Phase 1 |
What the finished NCT02635672 record still lists
NCT02635672 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% higher).
The record links to 0 conditions, and to 4 interventions - of which Keytruda is the first listed.
NCT02635672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02635672 about?
NCT02635672 is a clinical study titled "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer". Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).
What is the current status of trial NCT02635672?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2016-02-10. Estimated completion is 2024-11-11.
What interventions are being tested in trial NCT02635672?
The interventions under investigation include: Keytruda (DRUG), VIP152 (BAY 1251152) (DRUG), VIP152 (BAY 1251152) 30 mg (DRUG), VIP152 (BAY 1251152) 15 mg (DRUG).
Who is sponsoring clinical trial NCT02635672?
This trial is sponsored by Vincerx Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02635672's enrollment target sits among peer trials
110 514th of 2000 higher than 1,479 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI